Synaptogenix (TAOX) Competitors $6.92 -0.04 (-0.57%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsSEC FilingsTrendsBuy This Stock TAOX vs. SAVA, TCRX, ANRO, SPRO, HLVX, CNTB, SKYE, ONCY, ATOS, and ANIXShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Cassava Sciences (SAVA), TScan Therapeutics (TCRX), Alto Neuroscience (ANRO), Spero Therapeutics (SPRO), HilleVax (HLVX), Connect Biopharma (CNTB), Skye Bioscience (SKYE), Oncolytics Biotech (ONCY), Atossa Genetics (ATOS), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors Cassava Sciences TScan Therapeutics Alto Neuroscience Spero Therapeutics HilleVax Connect Biopharma Skye Bioscience Oncolytics Biotech Atossa Genetics Anixa Biosciences Synaptogenix (NASDAQ:TAOX) and Cassava Sciences (NASDAQ:SAVA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations. Does the media prefer TAOX or SAVA? In the previous week, Synaptogenix and Synaptogenix both had 1 articles in the media. Synaptogenix's average media sentiment score of 1.87 beat Cassava Sciences' score of 0.94 indicating that Synaptogenix is being referred to more favorably in the media. Company Overall Sentiment Synaptogenix Very Positive Cassava Sciences Positive Is TAOX or SAVA more profitable? Cassava Sciences' return on equity of -66.16% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -277.76% -150.79% Cassava Sciences N/A -66.16%-53.11% Do institutionals & insiders believe in TAOX or SAVA? 10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 12.2% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer TAOX or SAVA? Cassava Sciences has a consensus price target of $2.00, indicating a potential downside of 13.42%. Given Cassava Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Cassava Sciences is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better earnings & valuation, TAOX or SAVA? Synaptogenix has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenix$3.96K6,090.37-$12.77M-$20.16-0.34Cassava SciencesN/AN/A-$24.34M-$2.55-0.91 Which has more risk & volatility, TAOX or SAVA? Synaptogenix has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -2.05, suggesting that its share price is 305% less volatile than the S&P 500. SummaryCassava Sciences beats Synaptogenix on 7 of the 12 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for TAOX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TAOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TAOX vs. The Competition Export to ExcelMetricSynaptogenixPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$24.13M$853.28M$2.55B$9.78BDividend YieldN/A4.84%2.53%4.04%P/E Ratio-0.341.1621.9126.39Price / Sales6,090.37138.93262.5486.63Price / CashN/A19.5623.5159.11Price / Book1.406.7733.916.62Net Income-$12.77M-$4.20M$26.72M$265.42M7 Day Performance-0.14%11.77%2.14%3.58%1 Month Performance-17.72%3.47%1.53%0.46%1 Year PerformanceN/A15.88%30.18%19.41% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TAOXSynaptogenixN/A$6.92-0.6%N/AN/A$24.13M$3.96K-0.344Positive NewsSAVACassava Sciences1.9553 of 5 stars$2.20+2.3%$2.00-9.1%-92.4%$106.28MN/A-0.8630TCRXTScan Therapeutics3.0988 of 5 stars$1.87+7.5%$7.80+317.1%-66.7%$105.83M$2.82M-1.72100ANROAlto Neuroscience1.8832 of 5 stars$3.91+8.8%$8.50+117.6%-64.4%$105.60MN/A-1.63N/ASPROSpero Therapeutics4.0688 of 5 stars$1.87+0.5%$5.00+167.4%+36.5%$105.23M$47.98M-1.91150HLVXHilleVax1.4392 of 5 stars$2.06-0.5%$2.00-2.9%+6.6%$103.29MN/A-1.4420CNTBConnect Biopharma3.4166 of 5 stars$1.83+5.8%$7.00+282.5%+69.6%$101.97M$26.03M0.00110Positive NewsGap UpSKYESkye Bioscience1.6194 of 5 stars$3.29-7.3%$15.50+371.1%-47.8%$101.95MN/A-3.1011ONCYOncolytics Biotech2.0158 of 5 stars$1.01flat$5.00+395.0%+6.3%$101.36MN/A-3.7430ATOSAtossa Genetics2.5097 of 5 stars$0.78+4.5%$6.17+693.1%-46.5%$100.43MN/A-3.388Positive NewsANIXAnixa Biosciences2.3985 of 5 stars$3.06+3.7%$9.00+194.1%-11.5%$98.57M$210K-8.055 Related Companies and Tools Related Companies Cassava Sciences Alternatives TScan Therapeutics Alternatives Alto Neuroscience Alternatives Spero Therapeutics Alternatives HilleVax Alternatives Connect Biopharma Alternatives Skye Bioscience Alternatives Oncolytics Biotech Alternatives Atossa Genetics Alternatives Anixa Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TAOX) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access